Browse our latest Cancer Biology articles

The anti-diabetic drug metformin, currently in clinical trials as a potential anti-cancer agent, reduces tumor growth by inhibiting mitochondrial complex I of human cancer cells.

Many extracellular matrix proteins that are up-regulated during breast tumor progression enhance metastasis, and some are prognostic indicators of poor survival.

The cancer drug vemurafenib has potent off-target effects on JNK signaling that contribute to the development of squamous cell carcinomas in humans and in mice.

Reduced expression of MYBL2 contributes to malignancies of the blood by permitting uncontrolled expansion of blood cell progenitors, implying a tumor suppressor function for this gene.

A study that models the evolution of drug resistance in tumors reveals that drugs are more effective when given in combination than sequentially, and that cure is much more likely when the drugs target different pathways.

A protein called PVRL4 has a central role in a number of cancers that originate in epithelial tissue, and anti-PVRL4 antibodies could be used to treat some of these cancers.

Mutagenesis studies identified an androgen receptor mutation that converts enzalutamide-a drug recently approved for the treatment of advanced prostate cancer-into an androgen receptor agonist, and modeling studies informed the design of novel drugs that are effective against the mutant receptor.

Cleavage of a membrane-bound transcription factor by the chemotherapeutic reagent doxorubicin can block the proliferation of tumor cells.